Occurrence of adverse events · cancer cachexia in adults
It is very uncertain whether multimodal intervention (exercise plus other interventions) plus… changes occurrence of adverse events compared with usual care (very low certainty).
1 finding from 1 review
Muscle endurance/strength outcomes · cancer cachexia in adults
1 finding from 1 review
Maximal and submaximal exercise capacity** Submaximal capacity · cancer cachexia in adults
1 finding from 1 review
Fatigue · cancer cachexia in adults
1 finding from 1 review
Health‐related quality of life · cancer cachexia in adults
1 finding from 1 review
Lean body mass · cancer cachexia in adults
1 finding from 1 review
Adherence to prescribed exercise programmes · cancer cachexia in adults
The review found no eligible studies for this question.
1 finding from 1 review
Number experiencing adverse effects · chronic pain (excluding headache) in adults
1 finding from 1 review
AEs · chronic pain (excluding headache) in adults
It is very uncertain whether CBT changes adverse events (number of people with adverse events) (Lower events… compared with TAU (post‐treatment) (very low certainty).
Reduction in pain intensity · chronic pain (excluding headache) in adults
It is very uncertain whether CBT changes pain intensity (number of people with ≥ 30 % improvement)… compared with TAU (at follow‐up) (very low certainty).
Intervention not reported
Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
50 participants
GRADE not reported
Intervention not reported
Duloxetine high dose RCTs: 14 Participants: 3683 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
14 participants
Low
Intervention not reported
Duloxetine standard dose RCTs: 18 Participants: 4959 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
18 participants
Moderate
Intervention not reported
Milnacipran high dose RCTs: 2 Participants: 1670 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 4 Participants: 1866 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
4 participants
Moderate
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1104 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Proportion of participants requiring further IOP‐lowering interventions (additional surgery, medications, or both) (lower number of events is better) · Participants with acute primary angle closure after initial medical treatment to lower intraocular pressure
It is very uncertain whether phacoemulsification changes proportion of participants requiring further IOP‐lowering… compared with laser peripheral iridotomy (very low certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in secondary interventions compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Additional analgesia required (escape analgesia)
Naproxen showed no clear difference in need for additional analgesia (self‐recorded) compared with placebo (low certainty).
1 finding from 1 review